Selamectin is formulated as a spot-on for cats and dogs
to control fleas (Ctenocephalides spp.) and flea-allergy
dermatitis, to prevent heartworm disease, and to control
ear mites (Otodectes cynotes) in cats and dogs. It is also
approved for the treatment and control of sarcoptic mange
(Sarcoptes scabiei) in dogs and hookworms (Ancylostoma
tubaeformis) and roundworms (Toxocara cati) in cats.
Selamectin is a macrocyclic lactone derivative of ivermectin, an anthelmintic that potentiates glutamate- and GABA-gated chloride channel opening in nematodes. At 0.1 μg/ml, selamectin is reported to inhibit growth in an H. contortus larval development assay.
Selamectin is a topical parasiticide and also used as a veterinary antihelminithic agent on animals.
Selamectin is a semi-synthetic avermectin derivative prepared by selective hydrolysis and oximation of doramectin. Selamectin is a potent nematocide used for the treatment of endo- and exo- parasites of domestic animals, notably cats and dogs. Like the other milbemycin/avermectins, selamectin selectively binds to parasite glutamate-gated chloride ion channels and disrupts neurotransmission leading to paralysis and death of the parasite.
ChEBI: Selamectin is a milbemycin.
Veterinary Drugs and Treatments
Topical selamectin (Revolution?—Pfizer) is indicated for flea infestations
(Ctenocephalides felis), prevention of heartworm disease
(Dirofilaria immitis), and for ear mites (Otodectes cynotis) in both
dogs and cats. Additionally in dogs, it is indicated for sarcoptic
mange (Sarcoptes scabeii), and tick infestations (Dermacentor variabilis).
In cats: hookworm (Ancylostoma tubaeforme) and roundworm
(Toxocara cati).
The product (Revolution?) is labeled as not effective against either
adult heartworms or clearing circulating microfilaria, but it
possibly may have some efficacy with prolonged, continuous administration
(Atkins 2007b).
Acute oral LD50 for rats: >1,600 mg/kg
